

DAFTAR PUSTAKA

- Abdel, M., Saeed, M., Mohamed, A. H., & Owaynat, A. H. (2022). Comparison between methylprednisolone infusion and dexamethasone in COVID-19 ARDS mechanically ventilated patients. *The Egyptian Journal of Internal Medicine* 2022 34:1, 34(1), 1–9. <https://doi.org/10.1186/S43162-022-00113-Z>
- Ahmed, H. Y., Papali, A., Haile, T., Shrestha, G. S., Schultz, M. J., Lundeg, G., & Akrami, K. M. (2021). Pragmatic recommendations for the management of anticoagulation and venous thrombotic disease for hospitalized patients with COVID-19 in low- And middle-income countries. *American Journal of Tropical Medicine and Hygiene*, 104(3), 99–109. <https://doi.org/10.4269/ajtmh.20-1305>
- Al-Horani, R. A. (2020). Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections. *American Journal of Cardiovascular Drugs*, 20(6), 1. <https://doi.org/10.1007/S40256-020-00438-6>
- Al-Samkari, H., Karp Leaf, R. S., Dzik, W. H., Carlson, J. C. T., Fogerty, A. E., Waheed, A., Goodarzi, K., Bendapudi, P. K., Bornikova, L., Gupta, S., Leaf, D. E., Kuter, D. J., & Rosovsky, R. P. (2020). COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. *Blood*, 136(4), 489. <https://doi.org/10.1182/BLOOD.2020006520>
- Alam, S., Kamal, T. B., Sarker, M. M. R., Zhou, J.-R., Rahman, S. M. A., & Mohamed, I. N. (2021). Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. *Frontiers in Pharmacology*, 12. <https://doi.org/10.3389/FPHAR.2021.659577>
- Alanagreh, L., Alzoughool, F., & Atoum, M. (2020). The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms. *Pathogens*, 9(5). <https://doi.org/10.3390/PATHOGENS9050331>
- Albisinni, R., Vitrone, M., Ursi, M. P., Spiezia, S., Salemme, A., Florio, L. L., Boccia, F., Iossa, D., Zampino, R., Atripaldi, L., Squillante, F., Maturo, N., Fraganza, F., Severino, S., Punzi, R., & Fiorentino, G. (2021). Clinical evaluation of the safety and efficacy of enoxaparin in patients with COVID-19. *Blood Transfusion = Trasfusione Del Sangue*. <https://doi.org/10.2450/2021.0221-21>
- Alexiou, G. A., Tzima, A., Lianos, G. D., Lampros, M., Sotiropoulos, A., Rizos, D., Ygropoulou, O., Zika, J., Alexiou, E. S., & Voulgaris, S. (2022). Neutrophil to lymphocyte ratio in the prediction of coagulopathy in traumatic

brain injury. *Biomarkers in Medicine*, 16(3), 163–168.
<https://doi.org/10.2217/BMM-2021-0582>

Alkhatip, A. A. A. M. M., Kamel, M. G., Hamza, M. K., Farag, E. M., Yassin, H. M., Elayashy, M., Naguib, A. A., Wagih, M., Abd-Elhay, F. A.-E., Algameel, H. Z., Yousef, M. A., Purcell, A., & Helmy, M. (2021). The diagnostic and prognostic role of neutrophil-to-lymphocyte ratio in COVID-19: a systematic review and meta-analysis. *Expert Review of Molecular Diagnostics*, 21(5), 1.
<https://doi.org/10.1080/14737159.2021.1915773>

Amir, T., Toujani, S., Khaled, S. Ben, Slim, A., Hedhli, A., Cheikhrouhou, S., Ouahchi, Y., Mjid, M., & Merai, S. (2018). The Neutrophil-lymphocyte ratio in patients with community-acquired pneumonia. *European Respiratory Journal*, 52(suppl 62), PA2620.
<https://doi.org/10.1183/13993003.CONGRESS-2018.PA2620>

Aslan, B., Akyüz, A., Işık, F., Çap, M., İnci, Ü., Kaya, İ., Karahan, M. Z., Aktan, A., Bilge, Ö., Özbek, M., Altıntaş, B., & Boyraz, B. (2021). The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19. *International Journal of Clinical Practice*, 75(9), e14467.
<https://doi.org/10.1111/IJCP.14467>

Becker, R. C. (2020). COVID-19 update: Covid-19-associated coagulopathy. *Journal of Thrombosis and Thrombolysis*, 50(1), 54–67.
<https://doi.org/10.1007/s11239-020-02134-3>

Bedel, C., Korkut, M., & Armağan, H. H. (2021). NLR, d-NLR and PLR can be affected by many factors. *International Immunopharmacology*, 90, 107154.
<https://doi.org/10.1016/J.INTIMP.2020.107154>

Billett, H. H., Reyes-Gil, M., Szymanski, J., Ikemura, K., Stahl, L. R., Lo, Y., Rahman, S., Gonzalez-Lugo, J. D., Kushnir, M., Barouqa, M., Golestaneh, L., & Bellin, E. (2020). Anticoagulation in COVID-19: Effect of Enoxaparin, Heparin, and Apixaban on Mortality. *Thrombosis and Haemostasis*, 120(12), 1691. <https://doi.org/10.1055/S-0040-1720978>

Biswas, M., Rahaman, S., Biswas, T. K., Haque, Z., & Ibrahim, B. (2021). Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. *Intervirology*, 64(1), 36–47. <https://doi.org/10.1159/000512592>

Bounds, E. J., & Kok, S. J. (2021). D Dimer. *StatPearls*.
<https://www.ncbi.nlm.nih.gov/books/NBK431064/>

Buenen, A. G., Sinkeldam, M., Maas, M. L., Verdonschot, M., & Wever, P. C. (2021). Prior use of anticoagulation is associated with a better survival in

COVID-19. *Journal of Thrombosis and Thrombolysis*, 52(4), 1207–1211.
<https://doi.org/10.1007/S11239-021-02486-4/TABLES/2>

Canoglu, K., & Saylan, B. (2020). Therapeutic dosing of low-molecular-weight heparin may decrease mortality in patients with severe COVID-19 infection. *Annals of Saudi Medicine*, 40(6), 462. <https://doi.org/10.5144/0256-4947.2020.462>

Cardillo, G., Viggiano, G. V., Russo, V., Mangiacapra, S., Cavalli, A., Castaldo, G., Agrusta, F., Bellizzi, A., Snr, Amitrano, M., Snr, Iannuzzo, M., Sacco, C., Lodigiani, C., Fontanella, A., Micco, P. Di, & Group, F. T. F. (2021). Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. *Journal of Blood Medicine*, 12, 69. <https://doi.org/10.2147/JBM.S285214>

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S. C., & Di Napoli, R. (2020). Features, Evaluation and Treatment Coronavirus (COVID-19). In *StatPearls*. StatPearls Publishing. <http://www.ncbi.nlm.nih.gov/pubmed/32150360>

Cevik, M., Kuppalli, K., Kindrachuk, J., & Peiris, M. (2020). Virology, transmission, and pathogenesis of SARS-CoV-2. *The BMJ*, 371. <https://doi.org/10.1136/bmj.m3862>

Chandra, A., Chakraborty, U., Ghosh, S., & Dasgupta, S. (2021). Anticoagulation in COVID-19: Current concepts and controversies. In *Postgraduate Medical Journal* (Vol. 0, pp. 1–8). BMJ Publishing Group. <https://doi.org/10.1136/postgradmedj-2021-139923>

Chua, C. X. K., Tan, J. H. I., & Bin Abd Razak, H. R. (2022). Enoxaparin Versus Direct Oral Anticoagulants for Venous Thromboembolism in Asians Undergoing Total Knee Arthroplasty: A Meta-Analysis and Systematic Review. *The Journal of Arthroplasty*, 37(3), 593-600.e1. <https://doi.org/10.1016/J.ARTH.2021.11.030>

Correa, T. D., Cordioli, R. L., Guerra, J. C. C., Da Silva, B. C., Rodrigues, R. D. R., De Souza, G. M., Midega, T. D., Campos, N. S., Carneiro, B. V., Campos, F. N. D., Guimarães, H. P., De Matos, G. F. J., De Aranda, V. F., & Ferraz, L. J. R. (2020). Coagulation profile of COVID-19 patients admitted to the ICU: An exploratory study. *PLoS ONE*, 15(12 December), e0243604. <https://doi.org/10.1371/journal.pone.0243604>

DeHaas, K. A. (2017). The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban. *American Society for Clinical Laboratory Science*, 30(1), 2–6. <https://doi.org/10.29074/ASCLS.30.1.2>

- Djaharuddin, I., Munawwarah, S., Nurulita, A., Ilyas, M., Tabri, N. A., & Lihawa, N. (2021). Comorbidities and mortality in COVID-19 patients. *Gaceta Sanitaria*, 35, S530. <https://doi.org/10.1016/J.GACETA.2021.10.085>
- Doucette, K., Latif, H., Vakiti, A., Tefera, E., Patel, B., & Fitzpatrick, K. (2020). Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese. *Advances in Hematology*, 2020. <https://doi.org/10.1155/2020/3890706>
- Drago, F., Gozzo, L., Li, L., Stella, A., & Cosmi, B. (2020). Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. *Frontiers in Pharmacology*, 11. <https://doi.org/10.3389/FPHAR.2020.579886>
- Filopei, J., Bondarsky, E. E., Ehrlich, M., Islam, M., Bajpayee, G., Pang, D., Shujaat, A., Rowland, J., & Steiger, D. J. (2020). Reducing length of stay with the direct oral anti-coagulants in low and intermediate risk pulmonary embolism: a single center experience. *Journal of Thrombosis and Thrombolysis* 2020 50:2, 50(2), 399–407. <https://doi.org/10.1007/S11239-020-02045-3>
- Ganesh, B., Rajakumar, T., Malathi, M., Manikandan, N., Nagaraj, J., Santhakumar, A., Elangovan, A., & Malik, Y. S. (2021). Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. In *Clinical Epidemiology and Global Health* (Vol. 10, p. 100694). Elsevier B.V. <https://doi.org/10.1016/j.cegh.2020.100694>
- Gao, Y. dong, Ding, M., Dong, X., Zhang, J. jin, Kursat Azkur, A., Azkur, D., Gan, H., Sun, Y. li, Fu, W., Li, W., Liang, H. ling, Cao, Y. yuan, Yan, Q., Cao, C., Gao, H. yu, Brügger, M. C., van de Veen, W., Sokolowska, M., Akdis, M., & Akdis, C. A. (2021). Risk factors for severe and critically ill COVID-19 patients: A review. *Allergy*, 76(2), 428–455. <https://doi.org/10.1111/ALL.14657>
- Giannis, D., Ziogas, I. A., & Gianni, P. (2020). Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *Journal of Clinical Virology*, 127, 104362. <https://doi.org/10.1016/j.jcv.2020.104362>
- Gibson, C. M. (2014). *International Society on Thrombosis and Haemostasis bleeding scale* - *wikidoc*. https://www.wikidoc.org/index.php/International_Society_on_Thrombosis_and_Haemostasis_bleeding_scale

- Gozzo, L., Viale, P., Longo, L., Vitale, D. C., & Drago, F. (2020). The Potential Role of Heparin in Patients With COVID-19: Beyond the Anticoagulant Effect. A Review. In *Frontiers in Pharmacology* (Vol. 11). Frontiers Media S.A. <https://doi.org/10.3389/fphar.2020.01307>
- Groß, S., Jahn, C., Cushman, S., Bär, C., & Thum, T. (2020). SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. *Journal of Molecular and Cellular Cardiology*, 144, 47–53. <https://doi.org/10.1016/j.yjmcc.2020.04.031>
- Guan, W., Liang, W., Zhao, Y., Liang, H., Chen, Z., Li, Y., Liu, X., Chen, R., Tang, C., Wang, T., Ou, C., Li, L., Chen, P., Sang, L., Wang, W., Li, J., Li, C., Ou, L., Cheng, B., ... He, J. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. *The European Respiratory Journal*, 55(5), 640. <https://doi.org/10.1183/13993003.00547-2020>
- Harper, P. L., Theakston, E., Ahmed, J., & Ockelford, P. (2007). D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. *Internal Medicine Journal*, 37(9), 607–613. <https://doi.org/10.1111/J.1445-5994.2007.01388.X>
- Hashem, M. K., Khedr, E. M., Daef, E., Mohamed-Hussein, A., Mostafa, E. F., Hassany, S. M., Galal, H., Hassan, S. A., Galal, I., Amin, M. T., & Hassan, H. M. (2021). Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer. *The Egyptian Journal of Bronchology* 2021 15:1, 15(1), 1–9. <https://doi.org/10.1186/S43168-021-00075-W>
- Hong, Y., Mansour, S., Alotaibi, G., Wu, C., & McMurtry, M. S. (2018). Effect of anticoagulants on admission rates and length of hospital stay for acute venous thromboembolism: A systematic review of randomized control trials. *Critical Reviews in Oncology/Hematology*, 125, 12–18. <https://doi.org/10.1016/J.CRITREVONC.2018.02.010>
- Hu, D., Lou, X., Meng, N., Li, Z., Teng, Y., Zou, Y., & Wang, F. (2021). Influence of age and gender on the epidemic of COVID-19. *Wiener Klinische Wochenschrift* 2021 133:7, 133(7), 321–330. <https://doi.org/10.1007/S00508-021-01816-Z>
- Huang, Y., Yang, C., Xu, X. feng, Xu, W., & Liu, S. wen. (2020). Structural and functional properties of SARS-CoV-2 spike protein: potential antiviral drug development for COVID-19. In *Acta Pharmacologica Sinica* (Vol. 41, Issue 9, pp. 1141–1149). Springer Nature. <https://doi.org/10.1038/s41401-020-0485-4>

- Hussain, M., Babar, M. Z. M., Akhtar, L., & Hussain, M. S. (2017). Neutrophil lymphocyte ratio (NLR): A well assessment tool of glycemic control in type 2 diabetic patients. *Pakistan Journal of Medical Sciences*, 33(6), 1366. <https://doi.org/10.12669/PJMS.336.12900>
- Iba, T., Levy, J. H., Levi, M., Connors, J. M., & Thachil, J. (2020). Coagulopathy of Coronavirus Disease 2019. *Critical Care Medicine*, 1358–1364. <https://doi.org/10.1097/CCM.0000000000004458>
- Ibrahim, M. E., AL-Aklobi, O. S., Abomughaid, M. M., & Al-Ghamdi, M. A. (2021). Epidemiological, clinical, and laboratory findings for patients of different age groups with confirmed coronavirus disease 2019 (COVID-19) in a hospital in Saudi Arabia. *PLOS ONE*, 16(4), e0250955. <https://doi.org/10.1371/JOURNAL.PONE.0250955>
- Jayaweera, M., Perera, H., Gunawardana, B., & Manatunge, J. (2020). Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. In *Environmental Research* (Vol. 188, p. 109819). Academic Press Inc. <https://doi.org/10.1016/j.envres.2020.109819>
- Ji, Y. L., WU, Y., QIU, Z., MING, H., ZHANG, Y., ZHANG, A. N., LENG, Y., & XIA, Z. Y. (2021). The Pathogenesis and Treatment of COVID-19: A System Review. In *Biomedical and Environmental Sciences* (Vol. 34, Issue 1, pp. 50–60). Elsevier Ltd. <https://doi.org/10.3967/bes2021.007>
- Jirak, P., van Almsick, V., Dimitroulis, D., Mirna, M., Seelmaier, C., Shomanova, Z., Wernly, B., Semo, D., Dankl, D., Mahringer, M., Lichtenauer, M., Hoppe, U. C., Reinecke, H., Pistulli, R., Larbig, R., & Motloch, L. J. (2022). Dexamethasone Improves Cardiovascular Outcomes in Critically Ill COVID-19, a Real World Scenario Multicenter Analysis. *Frontiers in Medicine*, 9. <https://doi.org/10.3389/FMED.2022.808221>
- Johnson, E. D., Schell, J. C., & Rodgers, G. M. (2019). The D-dimer assay. *American Journal of Hematology*, 94(7), 833–839. <https://doi.org/10.1002/AJH.25482>
- Julia, S., & James, U. (2017). Direct Oral Anticoagulants: A Quick Guide. *European Cardiology Review*, 12(1), 40. <https://doi.org/10.15420/ECR.2017:11:2>
- Jupalli, A., & Iqbal, A. M. (2021). Enoxaparin. *XPharm: The Comprehensive Pharmacology Reference*, 1–4. <https://www.ncbi.nlm.nih.gov/books/NBK539865/>
- Kaptein, F. H. J., Stals, M. A. M., Huisman, M. V., & Klok, F. A. (2021).

Prophylaxis and treatment of COVID-19 related venous thromboembolism.
Postgraduate Medicine, 1–9.
<https://doi.org/10.1080/00325481.2021.1891788>

Karia, R., Gupta, I., Khandait, H., Yadav, A., & Yadav, A. (2020). COVID-19 and its Modes of Transmission. *SN Comprehensive Clinical Medicine*, 2(10), 1798–1801. <https://doi.org/10.1007/s42399-020-00498-4>

Kato, E. T., Giugliano, R. P., Ruff, C. T., Koretsune, Y., Yamashita, T., Kiss, R. G., Nordio, F., Murphy, S. A., Kimura, T., Jin, J., Lanz, H., Mercuri, M., Braunwald, E., & Antman, E. M. (2016). Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. *Journal of the American Heart Association*, 5(5). <https://doi.org/10.1161/JAHA.116.003432>

Khajuria, A., Bobdey, S., Kumar, S., Sahu, R., Vashisht, R., Bhaskar, V., Faujdar, D., Yadav, A., Kaushik, S., & Bhatia, S. (2021). An analysis of length of hospital stay of COVID-19 patients admitted in a dedicated COVID-19 hospital. *Journal of Marine Medical Society*, 0(0), 0. https://doi.org/10.4103/JMMS.JMMS_156_20

Kirchhof, P., Ezekowitz, M. D., Purmah, Y., Schiffer, S., Meng, I. L., Camm, A. J., Hohnloser, S. H., Schulz, A., Wosnitza, M., & Cappato, R. (2020). Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. *TH Open: Companion Journal to Thrombosis and Haemostasis*, 4(1), e20. <https://doi.org/10.1055/S-0040-1701206>

Komiyama, M., & Hasegawa, K. (2020). Anticoagulant therapy for patients with coronavirus disease 2019: Urgent need for enhanced awareness. In *European Cardiology Review* (Vol. 15). Radcliffe Cardiology. <https://doi.org/10.15420/ecr.2020.24>

Kuikel, S., Pathak, N., Poudel, S., Thapa, S., Bhattarai, S. L., Chaudhary, G., & Pandey, K. R. (2022). Neutrophil–lymphocyte ratio as a predictor of adverse outcome in patients with community-acquired pneumonia: A systematic review. *Health Science Reports*, 5(3). <https://doi.org/10.1002/HSR2.630>

Lee, S. R., Choi, E. K., Han, K. Do, Jung, J. H., Oh, S., & Lip, G. Y. H. (2019). Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. *Scientific Reports*, 9(1). <https://doi.org/10.1038/S41598-019-43224-4>

Lemeshow, S., Hosmer Jr, D. W., Klar, J., & Lwanga, S. K. (1990). *Adequacy of Sample Size in Health Studies*. World Health Organization. <https://apps.who.int/iris/handle/10665/41607>

- Levi, M., Thachil, J., Iba, T., & Levy, J. H. (2020). Coagulation abnormalities and thrombosis in patients with COVID-19. In *The Lancet Haematology* (Vol. 7, Issue 6, pp. e438–e440). Elsevier Ltd. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)
- Li, B., Wang, K., Zhao, X., Lin, C., & Sun, H. (2015). Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection. *Chinese Journal of Traumatology - English Edition*, 18(3), 147–149. <https://doi.org/10.1016/j.cjtee.2015.04.003>
- Li, X., Liu, C., Mao, Z., Xiao, M., Wang, L., Qi, S., & Zhou, F. (2020). Predictive values of neutrophil-to-lymphocyte ratio on disease severity and mortality in COVID-19 patients: a systematic review and meta-analysis. *Critical Care*, 24(1). <https://doi.org/10.1186/S13054-020-03374-8>
- Liu, H., Hu, T., Zhang, C., Chen, X., Zhang, S., Li, M., Jing, H., Wang, C., Hu, T., & Shi, J. (2021). Mechanisms of COVID-19 thrombosis in an inflammatory environment and new anticoagulant targets. In *Am J Transl Res* (Vol. 13, Issue 5). e-Century Publishing Corporation. www.ajtr.org
- Liu, Y., Du, X., Chen, J., Jin, Y., Peng, L., Wang, H. H. X., Luo, M., Chen, L., & Zhao, Y. (2020). Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *The Journal of Infection*, 81(1), e6. <https://doi.org/10.1016/J.JINF.2020.04.002>
- Long, A., Zhang, L., Zhang, Y., Jiang, B., Mao, Z., Li, H., Zhang, S., Xie, Z., & Tang, P. (2014). Efficacy and safety of rivaroxaban versus low-molecular-weight heparin therapy in patients with lower limb fractures. *Journal of Thrombosis and Thrombolysis* 2014 38:3, 38(3), 299–305. <https://doi.org/10.1007/S11239-013-1046-1>
- Lopes, R. D., de Barros e Silva, P. G. M., Furtado, R. H. M., Macedo, A. V. S., Bronhara, B., Damiani, L. P., Barbosa, L. M., de Aveiro Morata, J., Ramacciotti, E., de Aquino Martins, P., de Oliveira, A. L., Nunes, V. S., Ritt, L. E. F., Rocha, A. T., Tramuja, L., Santos, S. V., Diaz, D. R. A., Viana, L. S., Melro, L. M. G., ... Berwanger, O. (2021). Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. *Lancet (London, England)*, 397(10291), 2253–2263. [https://doi.org/10.1016/S0140-6736\(21\)01203-4](https://doi.org/10.1016/S0140-6736(21)01203-4)
- Lotfi, M., Hamblin, M. R., & Rezaei, N. (2020). COVID-19: Transmission, prevention, and potential therapeutic opportunities. In *Clinica Chimica Acta* (Vol. 508, pp. 254–266). Elsevier B.V.

<https://doi.org/10.1016/j.cca.2020.05.044>

Luo, X., Zhou, W., Yan, X., Guo, T., Wang, B., Xia, H., Ye, L., Xiong, J., Jiang, Z., Liu, Y., Zhang, B., & Yang, W. (2020). Prognostic value of C-reactive protein in patients with COVID-19. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 71(16), 2174–2179. <https://doi.org/10.1093/CID/CIAA641>

Magnani, G., Ardissino, D., Im, K., Budaj, A., Storey, R. F., Steg, P. G., Bhatt, D. L., Cohen, M., Ophius, T. O., Goudev, A., Parkhomenko, A., Kamensky, G., Angiolillo, D. J., López-Sendón, J., Johanson, P., Braunwald, E., Sabatine, M. S., & Bonaca, M. P. (2021). Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction. *Journal of the American Heart Association*, 10(4), 1–9. <https://doi.org/10.1161/JAHA.120.017008>

Mahardika, G. S., Tedjamartono, T. D., & Buwono, P. W. (2022). *High D-dimer and CRP Levels in an Asymptomatic COVID-19 Patient: A Case Report and Brief Literature Review* / Mahardhika / Seminar Nasional Riset Kedokteran. Seminar Nasional Riset Kedokteran. <https://conference.upnvj.ac.id/index.php/sensorik/article/view/1024>

Mai, F., Pinto, R. Del, & Ferri, C. (2020). COVID-19 and cardiovascular diseases. *Journal of Cardiology*, 76(5), 453–458. <https://doi.org/10.1016/J.JJCC.2020.07.013>

Man, M. A., Rajnoveanu, R.-M., Motoc, N. S., Bondor, C. I., Chis, A. F., Lesan, A., Puiu, R., Lucaciu, S.-R., Dantes, E., Gergely-Domokos, B., & Fira-Mladinescu, O. (2021). Neutrophil-to-lymphocyte ratio, platelets-to-lymphocyte ratio, and eosinophils correlation with high-resolution computer tomography severity score in COVID-19 patients. *PLOS ONE*, 16(6), e0252599. <https://doi.org/10.1371/JOURNAL.PONE.0252599>

Marik, P. E., Deperrior, S. E., Ahmad, Q., & Dodani, S. (2021). Gender-based disparities in COVID-19 patient outcomes. *Journal of Investigative Medicine*, 69(4), 814–818. <https://doi.org/10.1136/JIM-2020-001641>

Meyerowitz, E. A., Richterman, A., Gandhi, R. T., & Sax, P. E. (2021). Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors. In *Annals of internal medicine* (Vol. 174, Issue 1, pp. 69–79). NLM (Medline). <https://doi.org/10.7326/M20-5008>

Mishra, Y., Pathak, B. K., Mohakuda, S. S., Tilak, T. V. S. V. G. K., Sen, S., P, H., Singh, R., & Singh, A. R. (2020). Relation of D-dimer levels of COVID-19 patients with diabetes mellitus. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*, 14(6), 1927–1930.

<https://doi.org/10.1016/J.DSX.2020.09.035>

Morici, N., Podda, G. M., Biocchi, S., Bonacchini, L., Merli, M., Trezzi, M., Massaini, G., Agostinis, M., Carloti, G., Saverio Serino, F., Gazzaniga, G., Barberis, D., Antolini, L., Grazia Valsecchi, M., & Cattaneo, M. (2022). Enoxaparin for thromboprophylaxis in hospitalized COVID-19 patients: The X-COVID-19 Randomized Trial. *European Journal of Clinical Investigation*, 52(5), e13735. <https://doi.org/10.1111/EJC.13735>

Nakamura, M., Wang, Y. Q., Wang, C., Oh, D., Yin, W. H., Kimura, T., Miyazaki, K., Abe, K., Mercuri, M., Lee, L. H., Segers, A., & Büller, H. (2015). Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial. *Journal of Thrombosis and Haemostasis*, 13(9), 1606–1614. <https://doi.org/10.1111/JTH.13055>

Nas, K., Eryilmaz, N., Geyik, M. F., & Altaş, A. (2021). COVID-19 inpatients with familial Mediterranean fever treated with colchicine: case based review. *Rheumatology International*, 41(4), 811. <https://doi.org/10.1007/S00296-021-04809-3>

Nehring, S. M., Goyal, A., Bansal, P., & Patel, B. C. (2021). C Reactive Protein. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK441843/>

Nisio, M. Di, Ageno, W., Rutjes, A. W. S., Pap, A. F., & Büller, H. R. (2017). Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists. *Thrombosis and Haemostasis*, 115(02), 424–432. <https://doi.org/10.1160/TH15-06-0474>

Orantes, L. D. C., Díaz, J. S. S., Moguel, K. G. P., Sánchez, E. E. A., Rodríguez, O. I. S., Rodríguez, O. I. S., Hernández, O. G., Huerta, A. E., Zamudio, A. A., Caicero, A. R. V., Segovia, O. G., PachecoPérez, E. J., Sereno, Á. E. M., Sánchez, E. R. C., Hernández, S. N. H., Medrano-Rios, L. J., & Rosas-Lozano, A. L. (2021). Oral anticoagulation with rivaroxaban as thromboprophylaxis in patients recovered from COVID-19 pneumonia in Veracruz, Mexico. *Journal of Anesthesia & Critical Care: Open Access*, Volume 13(Issue 1), 12–15. <https://doi.org/10.15406/JACCOA.2021.13.00463>

Ortega-Paz, L., Capodanno, D., Montalescot, G., & Angiolillo, D. J. (2021). Coronavirus disease 2019–associated thrombosis and coagulopathy: Review of the pathophysiological characteristics and implications for antithrombotic management. *Journal of the American Heart Association*, 10(3), 1–24. <https://doi.org/10.1161/JAHA.120.019650>

Parimoo, A., Biswas, A., Baitha, U., Gupta, G., Pandey, S., Ranjan, P., Gupta, V.,

- Roy, D. B., Prakash, B., & Wig, N. (2021). Dynamics of Inflammatory Markers in Predicting Mortality in COVID-19. *Cureus*, 13(10). <https://doi.org/10.7759/CUREUS.19080>
- Pawlowski, C., Venkatakrishnan, A., Kirkup, C., Berner, G., Puranik, A., O'Horo, J. C., Badley, A. D., & Soundararajan, V. (2021). Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients. *EClinicalMedicine*, 33, 100774. <https://doi.org/10.1016/J.ECLINM.2021.100774>
- Perepu, U. S., Chambers, I., Wahab, A., Ten Eyck, P., Wu, C., Dayal, S., Sutamtewagul, G., Bailey, S. R., Rosenstein, L. J., & Lentz, S. R. (2021). Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial. *Journal of Thrombosis and Haemostasis*, 19(9), 2225–2234. <https://doi.org/10.1111/JTH.15450>
- Poudel, A., Poudel, Y., Adhikari, A., Aryal, B. B., Dangol, D., Bajracharya, T., Maharjan, A., & Gautam, R. (2021). D-dimer as a biomarker for assessment of COVID-19 prognosis: D-dimer levels on admission and its role in predicting disease outcome in hospitalized patients with COVID-19. *PLOS ONE*, 16(8), e0256744. <https://doi.org/10.1371/JOURNAL.PONE.0256744>
- Prasetya, I. B., Cucunawangsih, Lorens, J. O., Sungono, V., El-Khobar, K. E., & Wijaya, R. S. (2021). Prognostic value of inflammatory markers in patients with COVID-19 in Indonesia. *Clinical Epidemiology and Global Health*, 11, 100803. <https://doi.org/10.1016/J.CEGH.2021.100803>
- Qeadan, F., Tingey, B., Gu, L. Y., Packard, A. H., Erdei, E., & Saeed, A. I. (2021). Prognostic Values of Serum Ferritin and D-Dimer Trajectory in Patients with COVID-19. *Viruses* 2021, Vol. 13, Page 419, 13(3), 419. <https://doi.org/10.3390/V13030419>
- Qin, C., Zhou, L., Hu, Z., Zhang, S., Yang, S., Tao, Y., Xie, C., Ma, K., Shang, K., Wang, W., & Tian, D.-S. (2020). Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clinical Infectious Diseases*, 71(15), 762–768. <https://doi.org/10.1093/CID/CIAA248>
- Radadiya, D., Devani, K., Brahmabhatt, B., & Reddy, C. (2021). Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? - A systematic review and network meta-analysis. *European Journal of Gastroenterology & Hepatology*, 33(1S Suppl 1), e50–e58. <https://doi.org/10.1097/MEG.0000000000002035>
- Rahman, H. S., Aziz, M. S., Hussein, R. H., Othman, H. H., Salih Omer, S. H., Khalid, E. S., Abdulrahman, N. A., Amin, K., & Abdullah, R. (2020). The

transmission modes and sources of COVID-19: A systematic review. In *International Journal of Surgery Open* (Vol. 26, pp. 125–136). Elsevier Ltd. <https://doi.org/10.1016/j.ijso.2020.08.017>

Ramacciotti, E., Barile Agati, L., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., de Oliveira, C. C. C., Lins dos Santos, J., Volpiani, G. G., Sobreira, M. L., Joviliano, E. E., Bohatch Júnior, M. S., da Fonseca, B. A. L., Ribeiro, M. S., Dusilek, C., Itinose, K., Sanches, S. M. V., de Almeida Araujo Ramos, K., de Moraes, N. F., Tierno, P. F. G. M. M., ... Barbosa Santos, M. V. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. *The Lancet*, 399(10319), 50–59. [https://doi.org/10.1016/S0140-6736\(21\)02392-8](https://doi.org/10.1016/S0140-6736(21)02392-8)

Rivera-Caravaca, J. M., Harrison, S. L., Buckley, B. J. R., Fazio-Eynullayeva, E., Underhill, P., Marín, F., & Lip, G. Y. H. (2021). Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. *Cardiovascular Diabetology* 2021 20:1, 20(1), 1–11. <https://doi.org/10.1186/S12933-021-01368-6>

Rostami, M., & Mansouritorghabeh, H. (2020). D-dimer level in COVID-19 infection: a systematic review. *Https://Doi.Org/10.1080/17474086.2020.1831383*, 13(11), 1265–1275. <https://doi.org/10.1080/17474086.2020.1831383>

Russo, V., Cardillo, G., Viggiano, G. V., Mangiacapra, S., Cavalli, A., Fontanella, A., Agrusta, F., Bellizzi, A., Amitrano, M., Iannuzzo, M., Sacco, C., Lodigiani, C., Castaldo, G., & Di Micco, P. (2020). Thromboprophylaxis With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study. *Frontiers in Medicine*, 7, 569567. <https://doi.org/10.3389/fmed.2020.569567>

Sahebkar, A., Serban, C., Mikhailidis, D. P., Undas, A., Lip, G. Y. H., Muntner, P., Bittner, V., Ray, K. K., Watts, G. F., Hovingh, G. K., Rysz, J., Kastelein, J. J. P., Banach, M., & Group, L. and B. P. M. C. (LBPMC). (2017). Association between statin use and plasma D-dimer levels. *Thrombosis and Haemostasis*, 114(09), 546–557. <https://doi.org/10.1160/TH14-11-0937>

Saint, C. A., Castelli, M. R., Crannage, A. J., Stacy, Z. A., & Hennessey, E. K. (2017). Comparison of hospital length of stay in patients treated with non-vitamin K oral anticoagulants or parenteral agents plus warfarin for venous thromboembolism. *SAGE Open Medicine*, 5, 205031211771962. <https://doi.org/10.1177/2050312117719628>

Santesmasses, D., Castro, J. P., Zenin, A. A., Shindyapina, A. V., Gerashchenko, M. V., Zhang, B., Kerepesi, C., Yim, S. H., Fedichev, P. O., & Gladyshev, V.

- N. (2020). COVID-19 is an emergent disease of aging. *Aging Cell*, 19(10), e13230. <https://doi.org/10.1111/ACEL.13230>
- Sanyaolu, A., Okorie, C., Marinkovic, A., Patidar, R., Younis, K., Desai, P., Hosein, Z., Padda, I., Mangat, J., & Altaf, M. (2020). Comorbidity and its Impact on Patients with COVID-19. *Sn Comprehensive Clinical Medicine*, 2(8), 1. <https://doi.org/10.1007/S42399-020-00363-4>
- Sarkar, S., Khanna, P., & Singh, A. K. (2021). The Impact of Neutrophil-Lymphocyte Count Ratio in COVID-19: A Systematic Review and Meta-Analysis: <https://doi.org/10.1177/08850666211045626>. <https://doi.org/10.1177/08850666211045626>
- Schol-Gelok, S., Hulle, T. van der, Biedermann, J. S., Gelder, T. van, Klok, F. A., Pol, L. M. van der, Versmissen, J., Huisman, M. V., & Kruip, M. J. H. A. (2018). Clinical effects of antiplatelet drugs and statins on D-dimer levels. *European Journal of Clinical Investigation*, 48(7), 12944. <https://doi.org/10.1111/ECI.12944>
- Shah, S., Shah, K., Patel, S. B., Patel, F. S., Osman, M., Velagapudi, P., Turagam, M. K., Lakkireddy, D., & Garg, J. (2020). Elevated d-Dimer Levels Are Associated With Increased Risk of Mortality in Coronavirus Disease 2019: A Systematic Review and Meta-Analysis. *Cardiology in Review*, 295–302. <https://doi.org/10.1097/CRD.0000000000000330>
- Sharifpour, M., Rangaraju, S., Liu, M., Alabyad, D., Nahab, F. B., Creel-Bulos, C. M., Jabaley, C. S., & Collaborative, on behalf of the E. C.-19 Q. & C. R. (2020). C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. *PLoS ONE*, 15(11). <https://doi.org/10.1371/JOURNAL.PONE.0242400>
- Shereen, M. A., Khan, S., Kazmi, A., Bashir, N., & Siddique, R. (2020). COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. In *Journal of Advanced Research* (Vol. 24, pp. 91–98). Elsevier B.V. <https://doi.org/10.1016/j.jare.2020.03.005>
- Shi, C., Wang, C., Wang, H., Yang, C., Cai, F., Zeng, F., Cheng, F., Liu, Y., Zhou, T., Deng, B., Vlodavsky, I., Li, J. P., & Zhang, Y. (2020). The Potential of Low Molecular Weight Heparin to Mitigate Cytokine Storm in Severe COVID-19 Patients: A Retrospective Cohort Study. *Clinical and Translational Science*, 13(6), 1087–1095. <https://doi.org/10.1111/CTS.12880>
- Siemons, L., Ten Klooster, P. M., Vonkeman, H. E., Van Riel, P. L. C. M., Glas, C. A. W., & Van De Laar, M. A. F. J. (2014). How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. *BMC Musculoskeletal Disorders*, 15(1).

<https://doi.org/10.1186/1471-2474-15-368>

Simadibrata, D. M., Calvin, J., Wijaya, A. D., & Ibrahim, N. A. A. (2021). Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis. *The American Journal of Emergency Medicine*, 42, 60. <https://doi.org/10.1016/J.AJEM.2021.01.006>

Singh, R., & Emmady, P. D. (2021). Rivaroxaban. *Krankenhauspharmazie*, 28(7), 289–291. <https://www.ncbi.nlm.nih.gov/books/NBK557502/>

Sizar, O., Khare, S., Jamil, R. T., & Talati, R. (2021). Statin Medications. *StatPearls*. <https://www.ncbi.nlm.nih.gov/books/NBK430940/>

Skjøth, F., Larsen, T. B., Rasmussen, L. H., & Lip, G. Y. H. (2014). Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. *Thrombosis and Haemostasis*, 111(5), 981–988. <https://doi.org/10.1160/TH14-02-0118>

Smilowitz, N. R., Kunichoff, D., Garshick, M., Shah, B., Pillinger, M., Hochman, J. S., & Berger, J. S. (2021). C-reactive protein and clinical outcomes in patients with COVID-19. *European Heart Journal*, 42(23), 2270. <https://doi.org/10.1093/EURHEARTJ/EHAA1103>

Song, A. B., Rosovsky, R. P., Connors, J. M., & Al-Samkari, H. (2019). Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. *Vascular Health and Risk Management*, 15, 175. <https://doi.org/10.2147/VHRM.S132556>

Soni, M., Gopalakrishnan, R., Vaishya, R., & Prabu, P. (2020). D-dimer level is a useful predictor for mortality in patients with COVID-19: Analysis of 483 cases. *Diabetes & Metabolic Syndrome*, 14(6), 2245. <https://doi.org/10.1016/J.DSX.2020.11.007>

Stoeckle, K., Witting, B., Kapadia, S., An, A., & Marks, K. (2022). Elevated inflammatory markers are associated with poor outcomes in COVID-19 patients treated with remdesivir. *Journal of Medical Virology*, 94(1), 384. <https://doi.org/10.1002/JMV.27280>

Stringer, D., Braude, P., Myint, P. K., Evans, L., Collins, J. T., Verduri, A., Quinn, T. J., Vilches-Moraga, A., Stechman, M. J., Pearce, L., Moug, S., McCarthy, K., Hewitt, J., Carter, B., & Collaborators, C. S. (2021). The role of C-reactive protein as a prognostic marker in COVID-19. *International Journal of Epidemiology*, 50(2), 420–429. <https://doi.org/10.1093/IJE/DYAB012>

Suprapti, B., Debora, L., Kusumawati, D., PS, A. D., T, G. N., Arini, M. N., &

- Aryanti, L. D. (2022). Analysis of Enoxaparin Effectiveness Based on COVID-19 Severity: A Study in a Secondary Hospital in Bandung, Indonesia. *Indonesian Journal of Pharmacy*, 32. <https://doi.org/10.22146/IJP.4133>
- Suri, A., Singh, N. K., & Perumal, V. (2022). Association of inflammatory biomarker abnormalities with mortality in COVID-19: a meta-analysis. *Bulletin of the National Research Centre* 2022 46:1, 46(1), 1–14. <https://doi.org/10.1186/S42269-022-00733-Z>
- Tang, N., Bai, H., Chen, X., Gong, J., Li, D., & Sun, Z. (2020). Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of Thrombosis and Haemostasis*, 18(5), 1094–1099. <https://doi.org/10.1111/JTH.14817>
- Tarp, S., Bartels, E. M., Bliddal, H., Furst, D. E., Boers, M., Danneskiold-Samsøe, B., Rasmussen, M., & Christensen, R. (2012). Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: A meta-analysis of randomized controlled trials. *Arthritis & Rheumatism*, 64(11), 3511–3521. <https://doi.org/10.1002/ART.34644>
- Tassiopoulos, A. K., Mofakham, S., Rubano, J. A., Labropoulos, N., Bannazadeh, M., Drakos, P., Volteas, P., Cleri, N. A., Alkadaa, L. N., Asencio, A. A., Oganov, A., Hou, W., Rutigliano, D. N., Singer, A. J., Vosswinkel, J., Talamini, M., Mikell, C. B., & Kaushansky, K. (2021). D-Dimer-Driven Anticoagulation Reduces Mortality in Intubated COVID-19 Patients: A Cohort Study With a Propensity-Matched Analysis. *Frontiers in Medicine*, 0, 45. <https://doi.org/10.3389/FMED.2021.631335>
- Terra, P. O. C., Donadel, C. D., Oliveira, L. C., Meneguetti, M. G., Auxiliadora-Martins, M., Calado, R. T., & De Santis, G. C. (2022). Neutrophil-to-lymphocyte ratio and D-dimer are biomarkers of death risk in severe COVID-19: A retrospective observational study. *Health Science Reports*, 5(2). <https://doi.org/10.1002/HSR2.514>
- Toori, K. U., Qureshi, M. A., Chaudhry, A., & Safdar, M. F. (2021). Neutrophil to lymphocyte ratio (NLR) in COVID-19: A cheap prognostic marker in a resource constraint setting. *Pakistan Journal of Medical Sciences*, 37(5), 1435. <https://doi.org/10.12669/PJMS.37.5.4194>
- TUNÇ, A., ÜNLÜBAŞ, Y., ALEMDAR, M., & AKYÜZ, E. (2020). Coexistence of COVID-19 and acute ischemic stroke report of four cases. *Journal of Clinical Neuroscience*, 77, 227–229. <https://doi.org/10.1016/J.JOCN.2020.05.018>
- Ullah, W., Thalambedu, N., Haq, S., Saeed, R., Khanal, S., Tariq, S., Roomi, S., Madara, J., Boigon, M., Haas, D. C., & Fischman, D. L. (2020). Predictability

of CRP and D-Dimer levels for in-hospital outcomes and mortality of COVID-19. *Https://Doi.Org/10.1080/20009666.2020.1798141*, 10(5), 402–408. <https://doi.org/10.1080/20009666.2020.1798141>

Villoteau, A., Asfar, M., Otekpo, M., Loison, J., Gautier, J., & Annweiler, C. (2021). Elevated C-reactive protein in early COVID-19 predicts worse survival among hospitalized geriatric patients. *PLoS ONE*, 16(9). <https://doi.org/10.1371/JOURNAL.PONE.0256931>

Wang, B., Li, R., Lu, Z., & Huang, Y. (2020). Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. *Aging (Albany NY)*, 12(7), 6049. <https://doi.org/10.18632/AGING.103000>

Wang, J., Saguner, A. M., An, J., Ning, Y., Yan, Y., & Li, G. (2020). Dysfunctional Coagulation in COVID-19: From Cell to Bedside. In *Advances in Therapy* (Vol. 37, Issue 7, pp. 3033–3039). Adis. <https://doi.org/10.1007/s12325-020-01399-7>

Wang, Z., Liu, Y., Wei, L., Ji, J. S., Liu, Y., Liu, R., Zha, Y., Chang, X., Zhang, L., Liu, Q., Zhang, Y., Zeng, J., Dong, T., Xu, X., Zhou, L., He, J., Deng, Y., Zhong, B., & Wu, X. (2022). What are the risk factors of hospital length of stay in the novel coronavirus pneumonia (COVID-19) patients? A survival analysis in southwest China. *PLOS ONE*, 17(1), e0261216. <https://doi.org/10.1371/JOURNAL.PONE.0261216>

Wenzler, E., Engineer, M. H., Yaqoob, M., & Benken, S. T. (2020). Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease. *TH Open: Companion Journal to Thrombosis and Haemostasis*, 4(4), e376. <https://doi.org/10.1055/S-0040-1720962>

Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. In *JAMA - Journal of the American Medical Association* (Vol. 324, Issue 8, pp. 782–793). American Medical Association. <https://doi.org/10.1001/jama.2020.12839>

Yitbarek, G. Y., Ayehu, G. W., Asnakew, S., Ayele, F. Y., Gare, M. B., Mulu, A. T., Dagnaw, F. T., & Melesie, B. D. (2021). The role of C-reactive protein in predicting the severity of COVID-19 disease: A systematic review. *SAGE Open Medicine*, 9, 205031212110507. <https://doi.org/10.1177/20503121211050755>

Yu, B., Li, X., Chen, J., Ouyang, M., Zhang, H., Zhao, X., Tang, L., Luo, Q., Xu, M., Yang, L., Huang, G., Liu, X., & Tang, J. (2020). Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective

analysis. *Journal of Thrombosis and Thrombolysis*, 50(3), 1.
<https://doi.org/10.1007/S11239-020-02171-Y>

Yu, H. H., Qin, C., Chen, M., Wang, W., & Tian, D. S. (2020). D-dimer level is associated with the severity of COVID-19. *Thrombosis Research*, 195, 219.
<https://doi.org/10.1016/J.THROMRES.2020.07.047>

Yuki, K., Fujiogi, M., & Koutsogiannaki, S. (2020). COVID-19 pathophysiology: A review. In *Clinical Immunology* (Vol. 215, p. 108427). Academic Press Inc.
<https://doi.org/10.1016/j.clim.2020.108427>

Zemer-Wassercug, N., Haim, M., Leshem-Lev, D., Orvin, K. L., Vaduganathan, M., Gutstein, A., Kadmon, E., Mager, A., Kornowski, R., & Lev, E. L. (2015). The effect of dabigatran and rivaroxaban on platelet reactivity and inflammatory markers. *Journal of Thrombosis and Thrombolysis*, 40(3), 340–346. <https://doi.org/10.1007/S11239-015-1245-Z/TABLES/4>

Zhan, H., Chen, H., Liu, C., Cheng, L., Yan, S., Li, H., & Li, Y. (2021). Diagnostic Value of D-Dimer in COVID-19: A Meta-Analysis and Meta-Regression. *Clinical and Applied Thrombosis/Hemostasis*, 27.
<https://doi.org/10.1177/10760296211010976>

Zhang, L., Yan, X., Fan, Q., Liu, H., Liu, X., Liu, Z., & Zhang, Z. (2020). D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *Journal of Thrombosis and Haemostasis*, 18(6), 1324–1329.
<https://doi.org/10.1111/JTH.14859>